Stephen K. Horrigan

Dr. Horrigan is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development. Prior to joining Noble, Dr. Horrigan was the Vice President of Research at Avalon Pharmaceuticals a wholly-owned subsidiary of Clinical Data, Inc. During his tenure at Avalon, he held several positions of increasing responsibility within the research organization while directing both internal and collaborative research programs. He also played a key leadership role in the development of the company’s unique genomic biomarker-driven R&D platform. Dr. Horrigan has a strong expertise in the cellular control mechanisms of cancer and the use of biomarkers for the discovery and development of therapeutics and has multiple publications and patents in this area. Prior to joining Avalon, Dr. Horrigan was Associate Professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center where he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics. He has also held positions at the University of Illinois, College of Medicine and the University of Chicago School of Medicine.